Edoxaban, OR (95% CI)	Apixaban, OR (95% CI)			Rivaroxaban, OR (95% CI)
Age
18–64	Reference		Reference		Reference
65–74	0.87†	(0.82–0.93)	0.95	(0.89–1.01)	0.91†	(0.87–0.95)
75–79	0.79†	(0.73–0.86)	0.92†	(0.86–0.99)	0.90†	(0.86–0.95)
80–84	0.81†	(0.75–0.88)	1.06	(0.99–1.14)	0.96	(0.91–1.01)
≥85	1.20*	(1.10–1.30)	1.47*	(1.37–1.59)	1.19*	(1.13–1.26)
Female	1.05	(1.00–1.10)	1.11*	(1.06–1.16)	1.10*	(1.06–1.13)
Selective key comorbidities
Myocardial infarction	1.05	(0.86–1.28)	1.11	(0.94–1.32)	1.25*	(1.11–1.42)
Congestive heart failure	0.87†	(0.82–0.92)	0.94†	(0.90–0.99)	1.04*	(1.00–1.08)
Cerebral vascular disease	0.67†	(0.61–0.74)	0.81†	(0.74–0.88)	0.82†	(0.77–0.87)
Dementia	1.07	(0.96–1.18)	1.09	(1.00–1.19)	1.08*	(1.01–1.15)
Rheumatic disease	1.63*	(1.44–1.84)	1.42*	(1.27–1.59)	1.09	(1.00–1.20)
Peptic ulcer	0.82†	(0.76–0.88)	0.88†	(0.82–0.93)	0.97	(0.92–1.01)
Mild liver disease	1.12*	(1.03–1.22)	1.05	(0.97–1.13)	1.04	(0.98–1.10)
Diabetes without chronic complication	0.88†	(0.83–0.93)	0.95†	(0.90–1.00)	0.95	(0.91–0.98)
Diabetes with chronic complication	1.23*	(1.12–1.34)	1.29*	(1.19–1.39)	1.05	(0.99–1.12)
Hemiplegia or paraplegia	0.78†	(0.66–0.91)	0.93	(0.82–1.05)	1.01	(0.93–1.11)
Renal disease	1.59*	(1.47–1.73)	1.77*	(1.65–1.90)	1.29*	(1.21–1.36)
Cancer	1.10*	(1.01–1.21)	1.10*	(1.02–1.19)	1.05	(0.99–1.12)
Severe liver disease	2.09*	(1.30–3.35)	1.54	(0.97–2.43)	1.53*	(1.06–2.21)
Metastatic cancer	1.17	(0.90–1.52)	1.17	(0.93–1.47)	1.22*	(1.02–1.46)
Hypertension	0.92†	(0.87–0.97)	0.98	(0.94–1.03)	0.98	(0.94–1.01)
Stroke/TIA	0.90	(0.81–1.00)	0.90†	(0.82–0.98)	0.85†	(0.79–0.90)
Bleeding history or predisposition	1.22*	(1.13–1.32)	1.20*	(1.12–1.28)	1.05	(0.99–1.10)

^a Less likely with dabigatran; ^†More likely with dabigatran; CI, confidence interval; NOAC, non–vitamin K antagonist oral anticoagulant; OR, odds ratio; TIA, transient ischemic attack.